Conference Call - Hemispherx Responds to TheStreet.com
StocksHaven Investments news portal takes a closer look at Hemispherx Biopharma (AMEX:HEB), which hopes its drug, Ampligen will be approved to treat Chronic Fatigue Syndrome (CFS).
At approximately 3:30pm EST, 5/29/09, StocksHaven Investments began the call conference scheduled with Chairman & CEO of Hemispherx BioPharma Inc., Dr. William Carter. The basis interview was with regards to TheStreet.com’s Adam Feuerstein’s recent article, “Hemispherx’s CFS Drug Is a Long Shot“. The interview was concluded as of 4:00pm EST, 5/29/09. Many issues and concerns of private individual investors were raised and answered in a both informative and intellectual manner by Dr. Carter.
For the full exclusive interview visit http://www.StocksHaven.com
Disclosure: Long-Term Position
About StocksHaven Investments
StocksHaven Investments can be found at StocksHaven.com. It is a company offering a news portal covering the world financial news and equities sector. It features its own blog, free level 2 quotes, discussion forum, investment dictionary, stock research reports, conference calls, news feeds, mailing list, videos, press release capability, stock commentaries, company reviews and other unique content including expert stock analysis from Michael Vlaicu. The company also offers PR relations and contracting services.
For more financial and investment news, visit www.StocksHaven.com
- Contact Information
- Michael Vlaicu
- Founder, Lead Investment Analyst
- StocksHaven Investments
- Contact via E-mail
This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.